Company Overview
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is a global biotechnology company and the world's undisputed leader in cystic fibrosis (CF) treatment, headquartered in Boston, Massachusetts. Founded in 1989 by Joshua Boger, Vertex pioneered the development of CFTR modulators — drugs that target the underlying cause of CF (a defective protein) rather than just managing symptoms. The company reported revenues of $10.7B in FY2024, up 12% year-over-year, with a near-monopoly on the CF treatment market.
Business Model & Competitive Advantage
Vertex's CF franchise is built on a succession of increasingly effective CFTR modulator drugs: Kalydeco (2012), Orkambi (2015), Symdeko/Symkevi (2018), and Trikafta/Kaftrio (2019) — the latter treating up to 90% of CF patients and generating over $9B in annual revenue alone. Trikafta has been transformational for the 40,000+ CF patients in the US and 90,000+ globally, dramatically improving lung function and quality of life. Beyond CF, Vertex is expanding into new therapeutic areas with significant pipeline assets: exa-cel (a gene-editing therapy with CRISPR Therapeutics for sickle cell disease, now approved as Casgevy), non-opioid pain treatment (suzetrigine/VX-548, approved January 2025 as Journavx), and kidney disease (VX-147 for APOL1-mediated kidney disease).
Competitive Landscape 2025–2026
Vertex trades on NASDAQ (VRTX) with a market cap of approximately $110B and has one of the strongest balance sheets in biotech (~$12B in cash). CEO Reshma Kewalramani has expanded the company's ambition from a single-disease franchise to a multi-disease platform company, with the non-opioid pain drug Journavx representing a potential blockbuster in a market worth $15B+.
Open Positions
Reddit Discussions
Key Differentiators
Market Leader
Vertex Pharmaceuticals is recognized as a market leader in the Healthcare Tech sector, demonstrating strong industry presence and customer trust.
Enterprise Scale
With $10700M in revenue, Vertex Pharmaceuticals operates at enterprise scale with proven market validation.
Frequently Asked Questions
Not So Random Others
YouShift
YouShift is a United States-based AI healthcare workforce management platform — building the operating system for healthcare staffing starting with AI-powered scheduling agents that replace the comple
Hermes Robotics
Hermes Robotics is an autonomous mobile robot (AMR) and warehouse automation company developing robots and software for logistics and fulfillment operations in warehouses, distribution centers, and ma
Brisk
Brisk is a functional beverage brand offering ready-to-drink iced tea and juice drinks, jointly owned by PepsiCo and Unilever under the Lipton brand partnership. Launched in the 1990s, Brisk positione
Bucket Robotics
Bucket Robotics is an autonomous mobile robot (AMR) company that designs modular, rapidly deployable robots for warehouse automation and industrial material handling. Unlike traditional warehouse auto
Altria
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and s
Dusty Robotics
Dusty Robotics is a Mountain View, California-based construction robotics company — backed with $69.5 million in total funding from Root Ventures, Scale Venture Partners, Canaan Partners, GRIDS Capita
Compare Vertex Pharmaceuticals with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Vertex Pharmaceuticals? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Vertex Pharmaceuticals Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Vertex Pharmaceuticals vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →